KEYTRUDA Ovarian Cancer Treatments: FDA Approves New Regimens for Platinum-Resistant Cases
KEYTRUDA Ovarian Cancer Treatments Gain FDA Nod
KEYTRUDA ovarian cancer treatments now include FDA-approved regimens of KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), each with paclitaxel ± bevacizumab, for adults with PD-L1+ (CPS ≥1) platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. As per the Merck announcement, these are the first PD-1 inhibitor approvals in this setting, backed by Phase 3 KEYNOTE-B96 data showing 28% lower risk of progression or death and 24% reduced death risk versus placebo plus paclitaxel ± bevacizumab. They expand vital options for patients facing poor prognosis after platinum failure.
Survival gains are reported in the KEYNOTE-B96 trial’s PD-L1+ (CPS ≥1) subgroup. Median PFS hit 8.3 months (95% CI, 7.0-9.4) with KEYTRUDA regimens versus 7.2 months (95% CI, 6.2-8.1) with placebo (HR=0.72 [95% CI, 0.58-0.89]; p=0.0014). Median OS reached 18.2 months (95% CI, 15.3-21.0) versus 14.0 months (95% CI, 12.5-16.1) (HR=0.76 [95% CI, 0.61-0.94]; p=0.0053). Among 643 patients, 72% qualified by PD-L1, 73% got bevacizumab, and 47% had platinum-free intervals under 3 months—proving relevance for high-risk cases.
KEYNOTE-B96 Trial Blueprint
The KEYNOTE-B96 (ENGOT-ov65) design: a multicenter, randomized, double-blind Phase 3 trial with 643 patients post one or two prior regimens for platinum-resistant recurrent ovarian, fallopian tube, or primary peritoneal carcinoma. Dosing included KEYTRUDA 400 mg or placebo every 6 weeks, paclitaxel 80 mg/m² on days 1, 8, 15 of 3-week cycles, and optional bevacizumab 10 mg/kg every 2 weeks—up to 24 months or RECIST v1.1 progression, assessed every 9 weeks initially. Primary endpoint: investigator-assessed PFS; OS was key secondary. In 463 PD-L1+ patients (median exposure 7.4 months), serious adverse events hit 54% but stayed manageable, affirming the benefit-risk balance.
Shifting Economics of Ovarian Cancer Care
Extending PFS/OS in 72% PD-L1+ trial patients could support premium pricing via QALYs, and integrate CPS testing—despite costs and 54% serious AEs like pneumonia (4.3%). Reimbursement may speed via prior authorizations and Merck programs, with real-world data key to payer talks and outcomes-based deals in biomarker-driven gynecologic oncology.
